Management reaffirmed full year 2025 financial guidance: revenue range of $818 million to $828 million, gross margin of 69.5% to 70%, adjusted OpEx between $562 million and $568 million, adjusted ...

Myriad Genetics has been treading water for the past six months, recording a small loss of 3.6% while holding steady at $5.66 ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the full commercial launch of FirstGene ® Multiple Prenatal Screen, the only lab ...

Myriad Genetics expands its testing portfolio and advances its Cancer Care Continuum strategy. Can reimbursement risks and cost pressures temper growth?

Burning Rock Biotech Limited (NASDAQ: BNR, “Burning Rock”) and Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad”) today announced ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers.

Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing. The site seeks to ...

Myriad Genetics (NASDAQ:MYGN) is gearing up to announce its quarterly earnings on Monday, 2026-02-23. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Piper Sandler has upgraded Myriad Genetics (NASDAQ:MYGN), a molecular diagnostic testing and precision medicine company. Analyst David Westenberg says Myriad Genetics’ management team set an overly ...

Myriad Genetics partners with broadcaster Hannah Storm to promote breast cancer risk assessment and the importance of family health history. Myriad Genetics, Inc. has announced a collaboration with ...